Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
Mallo
Mar
M
Salido
Marta
M
Espinet
Blanca
B
Cervera
José
J
Canellas
Anna
A
Pajuelo
Juan Carlos
JC
Pedro
Carmen
C
Florensa
Lourdes
L
Sanz
Miguel Angel
MA
Solé
Francesc
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002869:Chromosome Aberrations / Q000187:drug effects*; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage
D004273:DNA, Neoplasm; D014212:Tretinoin; D015255:Idarubicin